Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Gonadotropin-releasing hormone Stories

2009-06-16 15:10:00

SAN DIEGO, June 16 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that data from Phase I and Phase II elagolix trials and preclinical work was presented at the 91st Annual Meeting of the Endocrine Society (ENDO 09) in Washington DC, June 10-13, 2009. The first clinical abstract presentation at ENDO 09 reviews the results of a Phase I study in which elagolix was evaluated over six weeks (42 days) in 60 healthy premenopausal women. The study was a...

2009-06-01 06:00:00

QUEBEC CITY, June 1 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that it presented results supporting the evaluation of its targeted cytotoxic peptide conjugate compound, AEZS-108 (formerly AN-152), in prostate cancer. The presentation was made during yesterday's poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held through June 2,...

2008-12-24 16:52:00

New Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist Demonstrates Rapid, Long-term Suppression of Testosterone - a hormone that stimulates prostate cancer growth. PARSIPPANY, N.J., Dec. 24 /PRNewswire/ -- Ferring Pharmaceuticals, USA today received approval from the U.S. Food and Drug Administration (FDA) for degarelix, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist, indicated for patients with advanced prostate cancer. Potential trade names are still...

2008-12-18 12:48:00

SAINT PREX, Switzerland, December 18 /PRNewswire/ -- - New Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist Demonstrates Rapid, Long-Term Suppression of Testosterone Ferring Pharmaceuticals received today notification that the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency (EMEA), has adopted a positive opinion and is recommending to grant a marketing authorization for FIRMAGON(R) (degarelix), a new GnRH receptor antagonist...

2008-12-12 10:29:44

A team of scientists from the University of Cambridge and the University of Cukurova in Turkey have taken a major step to understanding how the brain controls the onset of puberty. The research, published in this week's Nature Genetics, identified the hormone Neurokinin B as a critical part of the control system that switches on the master regulator of human puberty. Although Neurokinin B was previously known to be present in the hypothalamus, the part of the brain that controls puberty, its...

2008-12-10 23:59:52

Treating prostate cancer patients by blocking hormonal activity does not appear to increase their risk of cardiovascular disease, U.S. researchers say. Researchers at the Massachusetts General Hospital said that since the male hormones -- androgens -- can accelerate the development of prostate cancer, reducing their activity is a standard part of treating the disease. GnRH agonist therapy is routinely administered to men whose cancer has spread beyond the prostate gland, and its use in...

2008-12-03 13:24:14

Degarelix avoids initial hormone surge seen in other drugsMore than 95 per cent of men who took degarelix for prostate cancer saw their testosterone levels fall dramatically as early as three days after they started treatment, according to a paper in the December issue of BJU International.They also experienced much greater falls in their prostate-specific antigen (PSA) levels at 14 and 28 days than men taking leuprolide.Researchers from Canada, the USA, France, Denmark and the Netherlands...

2008-10-20 03:00:18

The international jury brought together by La Fondation Ipsen on June 2, 2006 in Toronto (Canada), under the presidency of Professor Iain Robinson (National Institute for Medical Research, London, UK) awarded the 6th Endocrine Communication and Regulation Prize to William F. Crowley (Harvard Medical School, Massachusetts General Hospital, Boston, USA) for his pioneering research on GnRH, a peptide hormone secreted by the hypothalamus which plays a role in the sexual development of humans. He...

2008-09-22 15:00:53

Internationally adopted children can undergo puberty at an early age making them more susceptible to health risks as adults, Canadian researchers said. University of Montreal researchers said that earlier puberty is linked to abdominal obesity, hypertension, diabetes, cardiovascular disease and certain cancers. "Many factors are at play but a low birth weight that isn't recuperated between the ages 0 and 2, combined with an accelerated weight gain during childhood, would increase the...

50833c301aa3780994debc32a05e2b2a
2008-09-03 13:35:00

Researchers say a small protein molecule in the brain plays a crucial ovulation-triggering role, a finding that could hold the key to new therapies for infertility. The protein, called kisspeptin, is known to play a vital role in kick-starting puberty. Now, the first evidence that kisspeptin signaling in the brain is also essential for ovulation to occur in adults has been published by a group from the University of Otago led by Professor Allan Herbison, in collaboration with Cambridge...